Andrée-Anne Grosset

Andrée-Anne Grosset

Auto-generated profile, based on publicly available information

Andrée-Anne Grosset

Centre de Recherche du Centre Hospitalier de l’Université de Montréal (CRCHUM), 900 Saint-Denis, Montreal, QC H2X 0A9, Canada

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 August 2020 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
AGAndrée-Anne Grosset
Andrée-Anne Grosset
FDFrédérick Dallaire
Frédérick Dallaire
TNTien Nguyen
Tien Nguyen
MBMirela Birlea
Mirela Birlea
JWJahg Wong
Jahg Wong
Dominique TrudelDominique Trudel
Dominique Trudel
Prostate cancer (PC) is the most frequently diagnosed cancer in North American men. Pathologists are in critical need of accurate biomarkers to characterize PC, particularly to confirm the presence of intraductal carcinoma of the prostate (IDC-P), an aggressive histopathological variant for which therapeutic options are now available. Our aim was to identify IDC-P with Raman micro-spectroscopy (RμS) and machine learning technology following a protocol suitable for routine clinical histopathology laboratories. We used RμS to differentiate IDC-P from PC, as well as PC and IDC-P from benign tissue on formalin-fixed paraffin-embedded first-line radical prostatectomy specimens (embedded in tissue microarrays [TMAs]) from 483 patients treated in 3 Canadian institutions between 1993 and 2013. The main measures were the presence or absence of IDC-P and of PC, regardless of the clinical outcomes. The median age at radical prostatectomy was 62 years. Most of the specimens from the first cohort (Centre hospitalier de l’Université de Montréal) were of Gleason score 3 + 3 = 6 (51%) while most of the specimens from the 2 other cohorts (University Health Network and Centre hospitalier universitaire de Québec–Université Laval) were of Gleason score 3 + 4 = 7 (51% and 52%, respectively). Most of the 483 patients were pT2 stage (44%–69%), and pT3a (22%–49%) was more frequent than pT3b (9%–12%). To investigate the prostate tissue of each patient, 2 consecutive sections of each TMA block were cut. The first section was transferred onto a glass slide to perform immunohistochemistry with H&E counterstaining for cell identification. The second section was placed on an aluminum slide, dewaxed, and then used to acquire an average of 7 Raman spectra per specimen (between 4 and 24 Raman spectra, 4 acquisitions/TMA core). Raman spectra of each cell type were then analyzed to retrieve tissue-specific molecular information and to generate classification models using machine learning technology. Models were trained and cross-validated using data from 1 institution. Accuracy, sensitivity, and specificity were 87% ± 5%, 86% ± 6%, and 89% ± 8%, respectively, to differentiate PC from benign tissue, and 95% ± 2%, 96% ± 4%, and 94% ± 2%, respectively, to differentiate IDC-P from PC. The trained models were then tested on Raman spectra from 2 independent institutions, reaching accuracies, sensitivities, and specificities of 84% and 86%, 84% and 87%, and 81% and 82%, respectively, to diagnose PC, and of 85% and 91%, 85% and 88%, and 86% and 93%, respectively, for the identification of IDC-P. IDC-P could further be differentiated from high-grade prostatic intraepithelial neoplasia (HGPIN), a pre-malignant intraductal proliferation that can be mistaken as IDC-P, with accuracies, sensitivities, and specificities > 95% in both training and testing cohorts. As we used stringent criteria to diagnose IDC-P, the main limitation of our study is the exclusion of borderline, difficult-to-classify lesions from our datasets. In this study, we developed classification models for the analysis of RμS data to differentiate IDC-P, PC, and benign tissue, including HGPIN. RμS could be a next-generation histopathological technique used to reinforce the identification of high-risk PC patients and lead to more precise diagnosis of IDC-P.

2 July 2019 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
AGAndrée-Anne Grosset
Andrée-Anne Grosset
VOVeronique Ouellet
Veronique Ouellet
CCChristine Caron
Christine Caron
GFGabriela Fragoso
Gabriela Fragoso
VBVéronique Barrès
Véronique Barrès
FNFor The Canadian Prostate Cancer Biomarker Network
For The Canadian Prostate Cancer Biomarker Network
The identification of patients with high-risk prostate cancer (PC) is a major challenge for clinicians, and the improvement of current prognostic parameters is an unmet clinical need. We and others have identified an association between the nuclear localization of NF-κB p65 and biochemical recurrence (BCR) in PC in small and/or single-centre cohorts of patients. In this study, we accessed 2 different multi-centre tissue microarrays (TMAs) representing cohorts of patients (Test-TMA and Validation-TMA series) of the Canadian Prostate Cancer Biomarker Network (CPCBN) to validate the association between p65 nuclear frequency and PC outcomes. Immunohistochemical staining of p65 was performed on the Test-TMA and Validation-TMA series, which include PC tissues from patients treated by first-line radical prostatectomy (n = 250 and n = 1,262, respectively). Two independent observers evaluated the p65 nuclear frequency in digital images of cancer tissue and benign adjacent gland tissue. Kaplan–Meier curves coupled with a log-rank test and univariate and multivariate Cox regression models were used for statistical analyses of continuous values and dichotomized data (cutoff of 3%). Multivariate analysis of the Validation-TMA cohort showed that p65 nuclear frequency in cancer cells was an independent predictor of BCR using continuous (hazard ratio [HR] 1.02 [95% CI 1.00–1.03], p = 0.004) and dichotomized data (HR 1.33 [95% CI 1.09–1.62], p = 0.005). Using a cutoff of 3%, we found that this biomarker was also associated with the development of bone metastases (HR 1.82 [95% CI 1.05–3.16], p = 0.033) and PC-specific mortality (HR 2.63 [95% CI 1.30–5.31], p = 0.004), independent of clinical parameters. BCR-free survival, bone-metastasis-free survival, and PC-specific survival were shorter for patients with higher p65 nuclear frequency (p < 0.005). As the small cores on TMAs are a limitation of the study, a backward validation of whole PC tissue section will be necessary for the implementation of p65 nuclear frequency as a PC biomarker in the clinical workflow. We report the first study using the pan-Canadian multi-centre cohorts of CPCBN and validate the association between increased frequency of nuclear p65 frequency and a risk of disease progression.

6 February 2022 in Cancers
Verified
Journal Article
Open access
PDF file
HPHelen Pantazopoulos
Helen Pantazopoulos
MDMame-Kany Diop
Mame-Kany Diop
AGAndrée-Anne Grosset
Andrée-Anne Grosset
FRFrédérique Rouleau-Gagné
Frédérique Rouleau-Gagné
AAAfnan Al-Saleh
Afnan Al-Saleh
Dominique TrudelDominique Trudel
Dominique Trudel
Intraductal carcinoma of the prostate (IDC-P) is one of the most aggressive types of prostate cancer (PCa). IDC-P is identified in approximately 20% of PCa patients and is associated with recurrence, metastasis, and PCa-specific death. The main feature of this histological variant is the colonization of benign glands by PCa cells. Although IDC-P is a well-recognized independent parameter for metastasis, mechanisms by which IDC-P cells can spread and colonize other tissues are not fully known. In this review, we discuss the molecular portraits of IDC-P determined by immunohistochemistry and genomic approaches and highlight the areas in which more research is needed.

6 November 2021 in Journal of Biomedical Optics
Verified
Journal Article
Open access
PDF file
APArthur Plante
Arthur Plante
FDFrédérick Dallaire
Frédérick Dallaire
AGAndrée-Anne Grosset
Andrée-Anne Grosset
TNTien Nguyen
Tien Nguyen
MBMirela Birlea
Mirela Birlea
FLFrédéric Leblond
Frédéric Leblond
Intraductal carcinoma of the prostate (IDC-P) is an aggressive variant of prostate cancer (PC) recognized as a distinct entity in 2016 by the World Health Organization classification.1 Current biomarkers used by pathologists for IDC-P identification, phosphatase and tensin homolog loss, and ETS-related gene overexpression, have low sensitivity limiting their use. However, by comparing PC and IDC-P Raman spectra, high sensitivity (≥85%) biomarkers were recently identified in our previous work and led to the first machine learning model for the diagnosis of IDC-P using Raman micro-spectroscopy (RμS).2 In this past study, Raman spectra from three institutes were collected independently to distinguish various types of prostate cancer on completely independent testing sets. Employing Raman spectroscopy for the identification of various pathologies is currently well-established.3

22 May 2017 in BMC Cancer
Verified
Journal Article
Open access
PDF file
VWVirginie Williams
Virginie Williams
AGAndrée-Anne Grosset
Andrée-Anne Grosset
NZNatalia Zamorano
Natalia Zamorano
YSYves St-Pierre
Yves St-Pierre
MSMarie-Pierre Sylvestre
Marie-Pierre Sylvestre
NGNathalie Grandvaux
Nathalie Grandvaux
IKKε is an oncogenic kinase that was found amplified and overexpressed in a substantial percentage of human breast cancer cell lines and primary tumors using genomic and gene expression analyses. Molecular studies have provided the rational for a key implication of IKKε in breast cancer cells proliferation and invasiveness through the phosphorylation of several substrates. Here, we performed immunohistochemical detection of IKKε expression on tissue microarrays constituted of 154 characterized human breast cancer tumors. We further determined the association with multiple clinicopathological parameters and 5-years overall, disease-free and distant disease free survival. We observed expression of IKKε in 60.4% of the breast cancer tumors. IKKε expression status showed no association with a panel of markers used for molecular classification of the tumors, including ER/PR/HER2 status, or with the molecular subtypes. However, IKKε expression was inversely associated with lymph node metastasis status (p = 0.0032). Additionally, we identified a novel association between IKKε and EGFR expression (p = 0.0011). The unexpected observation of an inverse association between IKKε and lymph node metastasis advocates for larger scale immunohistochemical profiling of primary breast tumors to clarify the role of IKKε in metastasis. This study suggests that breast cancer tumors expressing EGFR and IKKε may be potential targets for drugs aiming at inhibiting IKKε activity or expression.

13 July 2021 in Cancers
Verified
Journal Article
Open access
PDF file
PMPaule Marcoux-Valiquette
Paule Marcoux-Valiquette
CDCécile Darviot
Cécile Darviot
LWLu Wang
Lu Wang
AGAndrée-Anne Grosset
Andrée-Anne Grosset
MKMorteza Hasanzadeh Kafshgari
Morteza Hasanzadeh Kafshgari
MMMichel Meunier
Michel Meunier
Reliable cytopathological diagnosis requires new methods and approaches for the rapid and accurate determination of all cell types. This is especially important when the number of cells is limited, such as in the cytological samples of fine-needle biopsy. Immunoplasmonic-multiplexed- labeling may be one of the emerging solutions to such problems. However, to be accepted and used by the practicing pathologists, new methods must be compatible and complementary with existing cytopathology approaches where counterstaining is central to the correct interpretation of immunolabeling. In addition, the optical detection and imaging setup for immunoplasmonic-multiplexed-labeling must be implemented on the same cytopathological microscope, not interfere with standard H&E imaging, and operate as a second easy-to-use imaging method. In this article, we present multiplex imaging of four types of nanoplasmonic markers on two types of H&E-stained cytological specimens (formalin-fixed paraffin embedded and non-embedded adherent cancer cells) using a specially designed adapter for SI dark-field microscopy. The obtained results confirm the effectiveness of the proposed optical method for quantitative and multiplex identification of various plasmonic NPs, and the possibility of using immunoplasmonic-multiplexed-labeling for cytopathological diagnostics.